Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status Prescription
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 62332-412; 43598-856; 57664-769; 62332-411; 62756-569; 0078-0469; 70771-1411; 66039-871; 69097-550; 70771-1471; 72647-371; 62512-0078; 68462-494; 69539-021; 31722-012; 69097-391; 57664-770; 58032-2017; 69539-200; 63278-1070; 72647-372; 46708-324; 69452-159; 62332-410; 53104-7713; 72606-014; 11722-040; 69097-570; 43598-851; 62332-324; 67877-549; 69539-022; 66022-0301; 0591-3853; 45963-456; 14501-0049; 46708-410; 62332-325; 46708-879; 72606-013; 62756-570; 69238-1486; 43598-854; 65085-0063; 62332-326; 69238-1704; 70710-1011; 59285-010; 46708-326; 70710-1012; 59651-419; 16714-995; 69539-199; 72205-076; 65727-037; 74436-0323; 57664-768; 68462-495; 46708-325; 69452-160; 0078-0713; 65015-738; 16714-993; 69097-393; 69097-560; 0078-0470; 31722-013; 69539-074; 43598-853; 70700-269; 70771-1409; 49706-2103; 70710-1277; 43598-855; 0078-0468; 65372-1164; 16714-994; 43598-852; 45963-455; 46708-412; 0078-0727; 70771-1472; 72647-373; 68462-496; 67877-553; 69238-1703; 45963-454; 69452-161; 0078-0654; 62756-568; 70771-1473; 69539-023; 67877-550; 0078-0720; 70710-1275; 31722-011; 72606-015; 70771-1410; 69539-075; 67877-551; 70710-1013; 67877-554; 72205-075; 0078-0656; 70700-270; 69238-1702; 0078-0655; 46708-411; 69097-392; 69539-073; 69238-1487; 67877-552; 70700-271; 70710-1276; 69238-1488
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure increased13.14.03.005--Not Available
Blood pressure systolic increased13.14.03.0060.011662%Not Available
Blood sodium decreased13.11.01.0120.017494%Not Available
Blood sodium increased13.11.01.0130.005831%Not Available
Blood testosterone decreased13.10.05.0040.005831%Not Available
Blood urea abnormal13.13.01.0050.011662%Not Available
Blood urea increased13.13.01.0060.052481%Not Available
Body temperature increased13.15.01.0010.011662%Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.002--Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.0010.040818%
Bronchospasm22.03.01.004; 10.01.03.012--
Burning sensation17.02.06.001; 08.01.09.029--Not Available
C-reactive protein increased13.09.01.0070.043734%Not Available
Calculus bladder20.04.02.0020.005831%Not Available
Calculus urinary20.04.02.0010.005831%Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.031184%
Cardiac failure congestive02.05.01.002--Not Available
Cardiac murmur13.14.01.0010.011662%Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cardiogenic shock24.06.02.006; 02.05.01.003--Not Available
Cardiomegaly02.04.02.0010.004564%Not Available
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Cataract06.06.01.0010.020409%
Cellulitis11.02.01.001; 23.09.01.001--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 28 Pages